



## A NEW *ent*-KAURANE DITERPENE GLYCOSIDE FROM SEEDS OF *Pharbitis nil*

Kyeong Wan Woo,<sup>1</sup> Kyoung Jin Park,<sup>1</sup> Sang Zin Choi,<sup>2</sup>  
Mi Won Son,<sup>2</sup> Ki Hyun Kim,<sup>1</sup> and Kang Ro Lee<sup>1\*</sup>

A new *ent*-kaurane diterpene glycoside, pharboside H (**1**), and three known compounds, benzyl  $\beta$ -D-glucopyranoside (**2**), 1-(4'-O-glucopyranosyl-4'-hydroxy-3',5'-dimethoxyphenyl)-2{2'',6''-dimethoxy-4''-[1-(E) propen-3-ol]-phenoxy}-propane-1,3-diol (**3**), and butyl caffeate (**4**), were isolated from the seeds of *Pharbitis nil*. The structure of the new compound **1** was elucidated by 1D and 2D data analysis and enzyme hydrolysis. All the isolated compounds **1–4** were reported from this source for the first time. Compounds **1–4** were tested for cytotoxicity against four human tumor cell lines in vitro using the sulforhodamine B bioassay.

**Keywords:** *Pharbitis nil*, Convolvulaceae, *ent*-kaurane type diterpene, pharboside H.


*Pharbitis nil* (Convolvulaceae) is an annual climbing herb widely distributed throughout Korea, Japan, and China [1]. In China, it has been used as folk medicine for the treatment of a variety of digestive problems [2]. Previous phytochemical investigation reported resin glycosides, triterpenoid saponins, and anthocyanins in the flowers and seeds of *P. nil* [3–5]. Its extract showed antitumor and antifungal activities in some biological studies [6]. Our group has been interested in the phytochemicals of *P. nil* seeds and investigated the intriguing biological compounds from the MeOH extracts. As a result, we have reported the isolation of *ent*-kaurane type diterpenes, lignans, phenolic amides, and allogibberic acid, most of which exhibited cytotoxic activity and the ability to inhibit NO production [7–9]. Interestingly, *ent*-kaurane type diterpenes were identified from genus *Pharbitis* for the first time in our group. As part of our continuing effort to search for *ent*-kaurane type diterpenes from *P. nil* seeds, we investigated further its *n*-BuOH-soluble fraction. Repeated column chromatographic purification resulted in the isolation of one new *ent*-kaurane type diterpene glycoside (**1**), named pharboside H, along with three known compounds (**2–4**). The structure of new compound was determined on the basis of 1D and 2D NMR spectroscopic data and chemical means.



1) Natural Products Laboratory, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-Ro, Jangan-ku, Suwon, Gyeonggi-do, Republic of Korea, fax: 82 31 290 7730, e-mail: krlee@skku.edu; 2) Dong-A Pharm Institute, Kiheung, 449-905, Yongin, Republic of Korea. Published in *Khimiya Prirodnykh Soedinenii*, No. 3, May–June, 2017, pp. 399–401. Original article submitted September 21, 2015.

TABLE 1.  $^1\text{H}$  (700 MHz) and  $^{13}\text{C}$  NMR (175 MHz) NMR Data of Compound **1** ( $\text{CD}_3\text{OD}$ ,  $\delta$ , ppm, J/Hz)

C atom	$\delta_{\text{H}}$	$\delta_{\text{C}}$	C atom	$\delta_{\text{H}}$	$\delta_{\text{C}}$
1	1.63 m, 1.12 m	38.7	15	2.24 (1H, d, J = 13.0)	46.4
2	1.60 m, 1.56 m	18.5		1.03 (1H, dd, J = 13.0, 3.0)	
3	2.05 m, 1.44 m	29.4	16	–	82.8
4	–	43.1	17	3.81 (1H, d, J = 10.0)	79.3
5	1.89 (1H, d, J = 6.0)	52.7		3.47 (1H, d, J = 10.0)	
6	4.67 (1H, t, J = 6.5)	85.4	18	1.30 s	26.0
7	4.20 (1H, d, J = 6.5)	72.5	19	–	185.1
8	–	47.0	20	0.88 s	21.1
9	1.55 m	57.5	1'	4.32 (1H, d, J = 7.5)	105.1
10	–	35.4	2'	3.25 m	75.3
11	1.42 m, 1.37 m	17.8	3'	3.39 m	78.1
12	2.08 m, 1.70 m	21.9	4'	3.33 m	71.7
13	2.11 m	39.3	5'	3.31 m	78.0
14	1.67 m, 1.57 m	34.7	6'	3.80 (1H, dd, J = 12.0, 3.5)	62.8
				3.68 (1H, dd, J = 12.0, 2.0)	

Fig. 1. Key HMBC,  $^1\text{H}$ – $^1\text{H}$  COSY, and NOESY correlations of **1**.

Compound **1** was isolated as a colorless gum. The molecular formula was determined as  $\text{C}_{26}\text{H}_{40}\text{O}_{10}$  from its positive-ion HR-QTOF-MS at  $m/z$  513.2698 [ $\text{M} + \text{H}$ ] $^+$  (calcd for  $\text{C}_{26}\text{H}_{41}\text{O}_{10}$ , 513.2700). The  $^1\text{H}$  NMR spectrum (Table 1) showed the signals of two oxygenated methine protons at  $\delta$  4.67 (1H, t,  $J = 6.5$  Hz, H-6) and 4.20 (1H, d,  $J = 6.5$  Hz, H-7), oxygenated methylene protons at  $\delta$  3.81 (1H, d,  $J = 10.0$  Hz, H-17 $\alpha$ ) and 3.47 (1H, d,  $J = 10.0$  Hz, H-17 $\beta$ ), and two tertiary methyl protons at  $\delta$  1.30 (3H, s, H-18) and 0.88 (3H, s, H-20). In the  $^{13}\text{C}$  NMR (including DEPT) spectrum, 26 carbon signals, composed of two methyls, eight methylenes, five methines, four quaternary, one carbonyl, and six glucose carbons were observed. The spectroscopic data of **1** were similar to those of 7 $\beta$ ,16 $\beta$ ,17-trihydroxy-*ent*-kauran-6 $\alpha$ ,19-olide [7] except for the presence of an additional glucose group at  $\delta$  4.32 (1H, d,  $J = 7.5$  Hz, H-1'), 3.80 (1H, dd,  $J = 12.0, 3.5$  Hz, H-6' $\alpha$ ), 3.68 (1H, dd,  $J = 12.0, 2.0$  Hz, H-6' $\beta$ ), 3.39 (1H, m, H-3'), 3.33 (1H, m, H-4'), 3.31 (1H, m, H-5'), and 3.25 (1H, m, H-2') in the  $^1\text{H}$  NMR, and at  $\delta$  105.1, 78.1, 78.0, 75.3, 71.7, and 62.8 in the  $^{13}\text{C}$  NMR [10]. The coupling constant ( $J = 7.5$  Hz) of the anomeric proton was shown to be of the  $\beta$ -form [7]. The position of glucose was confirmed by an HMBC experiment, in which long-range correlations were observed between H-1' ( $\delta$  4.32) and C-17 ( $\delta$  79.3) (Fig. 1). The relative configuration of aglycone was confirmed to be the same as 7 $\beta$ ,16 $\beta$ ,17-trihydroxy-*ent*-kauran-6 $\alpha$ ,19-olide from the NOESY cross-peaks of H-5/H-6, H-18/H-6, H-5/H-9, H-7/H-14, and H-13/H-17 (Fig. 1) [7]. Enzyme hydrolysis of **1** yielded the aglycone and  $\beta$ -D-glucose. The former was identified by comparison of the  $^1\text{H}$  NMR data with the previous reference [7], and the latter from the co-TLC system and specific rotation value [10]. Thus, the structure of **1** was determined to be 7 $\beta$ ,16 $\beta$ ,17-trihydroxy-*ent*-kauran-6 $\alpha$ ,19-olide 17- $\beta$ -D-glucopyranoside and named pharboside H. To the best of our knowledge, this is the first report of the presence of an *ent*-kaurane type diterpene glycoside with a  $\gamma$ -lactone-ring in a natural product.

The other known compounds were identified as benzyl  $\beta$ -D-glucopyranoside (**2**) [11], 1-(4'-*O*-glucopyranosyl-4'-hydroxy-3',5'-dimethoxyphenyl)-2{2'',6''-dimethoxy-4''-[1-(*E*)propen-3-ol]-phenoxy}-propane-1,3-diol (**3**) [12], and butyl caffeate (**4**) [13] by comparison of their spectroscopic data with those in the literature. All the isolated known compounds (**2–4**) were reported from this source for the first time.

The isolated compounds **1–4** were tested for their cytotoxicity against four human tumor cells, A549 (non-small cell lung carcinoma), SK-OV-3 (ovarian cancer ascites), SK-MEL-2 (skin melanoma), and HCT-15 (colon adenocarcinoma) using the SRB assay [14]. Among the isolates **1–4**, the new one (**1**) showed the most potent cytotoxicity against A549, SK-OV-3, SK-MEL-2, and HCT15 cell lines ( $IC_{50}$  21.74, 5.92, 15.31, and 17.27 mM, respectively), but the other compounds showed little cytotoxicity ( $IC_{50} > 30$  mM).

## EXPERIMENTAL

**General.** TLC was performed using Merck precoated Silica gel F<sub>254</sub> plates and RP-18 F<sub>254</sub>s plates. Spots were detected on thin layer chromatography (TLC) under UV light or by heating after spraying with 10% H<sub>2</sub>SO<sub>4</sub> in C<sub>2</sub>H<sub>5</sub>OH (v/v). Semipreparative HPLC was performed using a Gilson 306 pump (Gilson, Middleton, WI) with a Shodex refractive index detector (Shodex, New York, NY) and Econosil<sup>®</sup> RP-C<sub>18</sub> 10 mm column (250 × 10 mm). Optical rotations were obtained on a JASCO P-1020 polarimeter (Jasco, Easton, MD). IR spectra were recorded on a Bruker IFS-66/S FT-IR spectrometer. NMR spectra, including <sup>1</sup>H–<sup>1</sup>H COSY, DEPT, HSQC, HMBC, NOESY experiments, were recorded on a Varian UNITY INOVA NMR spectrometer, with chemical shifts given in ppm ( $\delta$ ) using TMS as an internal standard. QTOF/MS was performed on a Waters Ultra-performance liquid chromatography–Xevo quadrupole-time of flight mass spectrometry (UPLC–qTOF–MS).

**Plant Material.** The seeds of *P. nil* were purchased at Kyungdong herbal market, Seoul, Korea, in July 2006, and were identified by one of the authors (K. R. Lee). A voucher specimen (SKKU 2006-7) has been deposited in the Herbarium of the School of Pharmacy, Sungkyunkwan University, Suwon, Korea.

**Extraction and Isolation.** The dried seeds of *P. nil* (10 kg) were extracted with 50% EtOH (4 L, 3 times, on each of 3 days) at room temperature and filtered. The filtrate was evaporated *in vacuo* to obtain the EtOH extract (1.0 kg), which was suspended in distilled H<sub>2</sub>O (7.2 L) and successively partitioned with *n*-hexane, CHCl<sub>3</sub>, EtOAc, and *n*-BuOH, to yield 4.7, 3.0, 13.1, and 270 g of dried organic extracts, respectively. The *n*-BuOH fraction (6 g) was chromatographed on a silica gel (230–400 mesh, 200 g) column and eluted with CHCl<sub>3</sub>–MeOH–H<sub>2</sub>O (7:3:0.5→1:1:1, gradient system) to yield three fractions (A–C). Fraction A (820 mg) was chromatographed further on an RP-C<sub>18</sub> silica gel (230–400 mesh, 150 g) column and eluted with MeOH–H<sub>2</sub>O (40→100% MeOH, gradient system) to obtain 19 subfractions (A1–A19). Subfraction A5 (17 mg) was purified by semipreparative reversed-phase HPLC using a solvent system of 20% MeCN to obtain **2** (3 mg) and **3** (3 mg). Subfraction A11 (20 mg) was purified by semipreparative reversed-phase HPLC using a solvent system of 25% MeCN to obtain **1** (6 mg). Subfraction A16 (40 mg) was purified by semipreparative reversed-phase HPLC using a solvent system of 45% MeCN to obtain **4** (19 mg).

**Pharboiside H (1).** Colorless gum.  $[\alpha]_D^{25} -5.3^\circ$  ( $c$  0.03; MeOH). IR (KBr,  $\nu$ , cm<sup>-1</sup>): 3374, 2947, 2835, 1748, 1651, 1451, 1021, 713. HR-QTOF-MS  $m/z$  513.2698 [M + H]<sup>+</sup> (calcd for C<sub>26</sub>H<sub>41</sub>O<sub>10</sub>, 513.2700). For <sup>1</sup>H NMR and <sup>13</sup>C NMR, see Table 1.

**Enzyme Hydrolysis and Sugar Identification.** Compound **1** (1.0 mg) in H<sub>2</sub>O (3 mL) was hydrolyzed with crude hesperidinase (30 mg, from *Aspergillus niger*, Sigma-Aldrich) at 37°C for 48 h. The reaction mixture was extracted with an equal amount of CHCl<sub>3</sub> (3 times), and the individual CHCl<sub>3</sub> extract was evaporated under reduced pressure. The combined CHCl<sub>3</sub> layers from **1** was purified on silica gel [Waters Sep-Pak Vac 6 cc (CHCl<sub>3</sub>–MeOH, 5:1)] to give 7 $\beta$ ,16 $\beta$ ,17-trihydroxy-*ent*-kauran-6 $\alpha$ ,19-olide (**5**), which was identified by comparing its <sup>1</sup>H NMR with that reported in the literature [9]. The aqueous phase of the hydrolysate of **1** were subjected separately to column chromatography over silica gel eluted with MeCN–H<sub>2</sub>O (8:1) to yield D-glucose with positive specific rotation  $[\alpha]_D^{25} +45.5^\circ$  ( $c$  0.04; H<sub>2</sub>O). The D-glucose was analyzed by silica gel co-TLC and by comparison with an authentic sample [solvent system CHCl<sub>3</sub>–MeOH–H<sub>2</sub>O, 6:4:1;  $R_f$  value 0.3] [14].

**Test for Cytotoxicity *in vitro*.** SRB bioassays were used as cytotoxicity screening methods. Cytotoxicity assays for each compound were performed *in vitro* against four cultured human tumor cell lines at the Korea Research Institute of Chemical Technology. The cell lines used were A549 (non-small cell lung adenocarcinoma), SK-OV-3 (ovarian cancer cells), SK-MEL-2 (skin melanoma), and HCT15 (colon cancer cells). Etoposide was used as the positive control.

## ACKNOWLEDGMENT

This research was supported by the Global Leading Technology Program of the Office of Strategic R&D Planning (OSP) funded by the Ministry of Knowledge Economy, Republic of Korea (10039303). We thank the Korea Basic Science Institute (KBSI) for the NMR and MS spectral measurements.

## REFERENCES

1. Y. N. Lee, *Flora of Korea*, Kyo-Hak Publishing Co, Seoul, 1996, 653 pp.
2. T. H. Lee, J. J. Choi, D. H. Kim, S. Choi, K. R. Lee, M. Son, and M. Jin, *Phytomedicine*, **15**, 836 (2008).
3. M. Ono, A. Takigawa, T. Mineno, H. Yoshimitsu, T. Nohara, T. Ikeda, E. Fukuda-Teramachi, N. Noda, and K. Miyahara, *J. Nat. Prod.*, **73**, 1846 (2010).
4. D. Y. Jung, H. Ha, H. Y. Lee, C. Kim, J. H. Lee, K. Bae, J. S. Kim, and S. S. Kang, *Chem. Pharm. Bull.*, **56**, 203 (2008).
5. N. Saito, F. Tatsuzawa, K. Kasahara, M. Yokoi, S. Iida, A. Shigihara, and T. Honda, *Phytochemistry*, **41**, 1607 (1996).
6. S. G. Ko, S. H. Koh, C. Y. Jun, C. G. Nam, H. S. Bae, and M. K. Shin, *Biol. Pharm. Bull.*, **27**, 1604 (2004).
7. K. H. Kim, S. U. Choi, and K. R. Lee, *J. Nat. Prod.*, **72**, 1121 (2009).
8. K. H. Kim, S. U. Choi, M. W. Son, S. Z. Choi, J. Clardy, and K. R. Lee, *J. Nat. Prod.*, **76**, 1376 (2013).
9. K. H. Kim, K. W. Woo, E. Moon, S. U. Choi, S. Y. Kim, S. Z. Choi, M. W. Son, and K. R. Lee, *J. Agric. Food Chem.*, **62**, 7746 (2014).
10. K. W. Woo, J. Y. Han, W. S. Suh, J. H. Lee, and K. R. Lee, *Bull. Korean Chem. Soc.*, **35**, 2151 (2014).
11. K. W. Woo and K. R. Lee, *Nat. Prod. Sci.*, **19**, 221 (2013).
12. K. Yoshikawa, S. Sugawara, and S. Arihara, *Phytochemistry*, **40**, 253 (1995).
13. K. Uwai, Y. Osanai, T. Imaizumi, S. Kanno, M. Takeshita, and M. Ishikawa, *Bioorg. Med. Chem.*, **16**, 7795 (2008).
14. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. MaMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd, *J. Natl. Cancer Inst.*, **82**, 1107 (1990).